Johns Hopkins All Children's Hospital

Solid Tumor Clinical Trials

Clinical trials at Johns Hopkins All Children’s Hospital provide patients access to research opportunities that provide the latest treatment options and improve solid tumor survival rates.

Your child can participate in Johns Hopkins clinical trials without leaving Florida. We collaborate with Johns Hopkins Medicine in Baltimore, the Children’s Oncology Group (COG), and multiple other national and international collaborations to provide the latest treatment options and improve solid tumor survival rates.

Johns Hopkins All Children’s Hospital is a non-core member of the Pediatric Early Phase Clinical Trials Network (PEP-CTN), an international group of leading pediatric oncology programs dedicated to conducting early phase clinical trials for pediatric cancers.

It is our goal to find breakthroughs in ways to treat solid tumors more safely and with fewer side effects.

Open Clinical Trials

J12106: A Phase II Trial of Reduced Intensity Conditioning of Partially HLA-mismatched (HLA-haploidentical) Related Donor Bone Marrow Transplant for High Risk solid tumors

J17124: Single-arm, open-label phase 1b/2 trial of Nivolumab therapy following partially HLA mismatched (haploidentical) bone marrow transplant in children and young adults with high risk, recurrent or refractory solid tumors (CA29-9AT)

A5481092: PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF  PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND  TEMOZOLOMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR  REFRACTORY SOLID TUMORS

AflacST1603: A Phase 1 Study Using Nab-paclitaxel (Abraxane) in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors

AGCT1531: AGCT1531, A PHASE 3 STUDY OF ACTIVE SURVEILLANCE FOR LOW RISK AND A RANDOMIZED TRIAL OF CARBOPLATIN VS. CISPLATIN FOR STANDARD RISK PEDIATRIC AND ADULT PATIENTS WITH GERM CELL TUMORS.

AHEP1531: Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

ANBL1232: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma. A Groupwide Historically Controlled Phase III Study

APEC1621A: NCI COG Pediatrics Match (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Loxo-101 (Larotrectinib) In Patients with Tumors Harboring Actionable NTRK Fusions

APEC1621B: NCI-COG Pediatric Match (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of JNJ-42756493 (ERDAFITINIB) in Patients with Tumors Harboring FGFRI 1/2/3/4 Alterations

APEC1621D: NCI-COG Pediatric Match (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Ly3023414 in Patients with Solid Tumors

APEC1621F: NCI-COG Pediatric Match (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROSI Genomic Alterations

APEC1621G: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Vemurafenib in patients with tumors harboring actionable BRAF V600 mutations

APEC1621I: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes

APEC1621J: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations

APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

ARST1431: A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

ARST1921: A Safety, Pharmacokinetic and Efficacy Study of a Gamma-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors

LCH-IV: LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis

MCC18613: Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults

MCC19487: A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma.

NMTRC014: NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)

Sala-002-EW16: Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients with Relapsed Or Refractory Ewing Sarcoma and Select Sarcomas

MCC20320: Blood Based Biomarkers For Minimal Residual Disease Detection in Pediatric Sarcoma

MCC20339: Evolutionary inspired therapy for newly diagnosed, metastatic, Fusion Positive Rhabdomyosarcoma

PEPN1924: Phase 2 Study of DS-8201a (NSC#807708, IND#153036) in Adolescents, or Young Adults with Recurrent HER2+ Osteosarcoma

TiLs: Use of Malignant Solid Tumor and Bone Marrow Specimens Not Required for Diagnostic Purposes and Peripheral Blood for Validation and Characterization of Tumor- and Marrow-Infiltrating Lymphocyte Growth Procedures